Oliver Fetzer, Ph.D.
President and Chief Executive Officer
Oliver has served as our chief executive officer since 2009. Prior to joining Cerulean, he was senior vice president, corporate development and research and development at Cubist Pharmaceuticals (NASDAQ: CBST). While at Cubist, his responsibilities included corporate development, business development, drug discovery research, non-clinical development, clinical development, chemical development, medical affairs, and program management. Previously, Oliver served as a managing director and partner at the Boston Consulting Group (BCG) in the firm’s healthcare practice, where he was responsible for projects in strategy, operational effectiveness, and mergers and integration. He worked with clients both in and outside of healthcare while he was stationed at the BCG offices located in Boston, Auckland, and Munich. While at BCG, Oliver also led the associate recruiting effort for the Boston office and was a member of the Career Development Committee. Early in his career, Oliver worked at Bayer AG, where he was involved in chemistry and pharmaceutics.
Oliver is presently a director of Auxilium Pharmaceuticals (NASDAQ: AUXL), Tecan Group AG (SWX: TECN), and Cerulean Pharma. He earned his B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.
Edward Garmey, M.D.
Chief Medical Officer and Senior Vice President
Edward has served as our chief medical officer since 2011. Previously, he was vice president for clinical development at ArQule, Inc., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Edward additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development, and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to ArQule, Edward was medical director at GPC Biotech, where he helped oversee global clinical development studies.
A pediatric hematologist-oncologist by training, Edward is a graduate of Harvard and New York Universities and completed his medical training at Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and the Memorial Sloan-Kettering Cancer Center. Edward completed additional research fellowships at the National Institutes of Health and Botswana-Harvard Partnership for HIV Research in Gaborone, Botswana. A recipient of young investigators awards from the American Society of Hematology and the American Heart Association, Edward has presented at numerous international conferences and is an author on over 30 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund and serves there as an advisor to the fund’s $1.25 million “BioAccelerate NYC Prize” for biomedical research. In Boston, Edward is a member of the Scientific Advisory Board for the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative, and he serves on the board of visitors of Hearth, a Boston-based non-profit organization dedicated to the elimination of homelessness among the elderly.
Christopher D. T. Guiffre, J.D.
Senior Vice President and Chief Business Officer
Chris has served as our chief business officer since 2012. Previously, he served as president and chief executive officer of Alvos Therapeutics, Inc., a biopharmaceutical company dedicated to developing “guided therapeutics” that destroy cancer cells while sparing normal tissues. Prior to Alvos, Chris was chief business officer at Hydra Biosciences, Inc., where he led the company’s partnering activities culminating in a transformational deal for the company’s lead TRP ion channel program. Before Hydra, Chris was senior vice president, general counsel, and secretary at Cubist Pharmaceuticals, where he oversaw legal, IP, compliance, risk management, government affairs, regulatory affairs, quality assurance, and quality control functions and was closely involved with the company’s commercial, finance, IR/PR, and business development activities during the company’s highly successful transition from an R&D company to a fully integrated commercial pharmaceutical company. Prior to his time at Cubist, Chris held positions of increasing responsibility at Renaissance Worldwide, Inc., including vice president, general counsel, and clerk, and he was an associate at Bingham, Dana & Gould (now known as Bingham McCutchen).
Chris earned a B.S. from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.
Senior Vice President, Finance and Administration
Karen has served as our head of finance and administration since 2010. Previously, she was vice president, finance and administration at Elixir Pharmaceuticals, Inc., a position she held since the company’s founding in 2001. At Elixir, Karen was a member of the executive team, responsible for all aspects of accounting, finance and administration. Prior to joining Elixir, Karen held senior financial positions where she was responsible for financial operations at Frontline Group, Dyax Corporation, and T Cell Sciences. Karen was recruited into life sciences from Avery Dennison, where she held numerous financial positions of increasing responsibility.
Karen is a member of the Financial Executives Institute’s Boston Chapter. Karen earned a B.S. in Business Administration from Salem State College.
Scott Eliasof, Ph.D.
Vice President, Research
Scott has led our research team since 2007 and has served as vice president of research since 2011. Previously, he was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science, and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.
Scott earned his B.S. from MIT in Electrical Engineering, Ph.D. from the University of California at Berkeley in Neuroscience, and completed his post-doctoral fellowship at the Vollum Institute in Portland, Oregon.
Vice President, Pharmaceutical Sciences and Manufacturing
Marc has led our analytical team since 2007 and has served as vice president of pharmaceutical sciences and manufacturing since 2011. Previously, he was senior director of quality at Momenta Pharmaceuticals, where he was responsible for building the quality affairs and quality control functions, including the establishment of an in-house cGMP testing laboratory. Prior to joining Momenta, he held various CMC related positions ranging from analytical development, QA/QC, production technology, and regulatory affairs at Millennium Pharmaceuticals, Biogen, and Boehringer Ingelheim.
Marc earned degrees in Biology and Chemistry from Pennsylvania State University and Montclair State University.